Follow us on:

Linkedin Facebook

AstraZeneca plc 16.8% Potential Upside Indicated by Deutsche Bank

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

AstraZeneca plc with EPIC/TICKER (LON:AZN) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Deutsche Bank. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set their target price at 6800 GBX on its stock. This is indicating the analyst believes there is a potential upside of 16.8% from today’s opening price of 5820 GBX. Over the last 30 and 90 trading days the company share price has decreased 300 points and increased 128 points respectively. The 1 year high stock price is 6540 GBX while the year low share price is currently 5110 GBX.

AstraZeneca plc has a 50 day moving average of 6,173.81 GBX and a 200 day moving average of 5,998.42. There are currently 1,311,759,192 shares in issue with the average daily volume traded being 3,049,485. Market capitalisation for LON:AZN is £77,393,792,328 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

    Latest Company News

    Broker Ratings

    AstraZeneca plc 38.4% potential upside indicated by JP Morgan

    AstraZeneca

    AstraZeneca Plc expands US R&D and manufacturing footprint with $3.5b investment

    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
    AstraZeneca

    AstraZeneca Plc Tezspire meets primary endpoints in WAYPOINT trial

    AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.
    AstraZeneca

    AstraZeneca’s Wainzua recommended for approval in the UK

    AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy.
    AstraZeneca

    AstraZeneca’s Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis

    Broker Ratings

    AstraZeneca plc -12.4% potential downside indicated by Deutsche

      Latest interviews

      View all interviews 

      Company Presentations

      View all Company Presentations

      Brokers Talk

      View all Broker Talk

      FTSE 100 News

      Search

      Search

      Green News

      View all Sustainable sectors, Plcs and news  

      Q&A's

      View all Question and Answers

      Funds

      View all Funds, Market Insights and news

      UK Broker Ratings

      Hardman & Co

      Don't Miss Our News Alerts

      Subscribe Free

      Find us on:

      Linkedin Facebook

      Useful links

      Disclaimer

      You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

      © 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.